UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (19) 19
life sciences & biomedicine (16) 16
science & technology (16) 16
middle aged (9) 9
oncology (9) 9
female (8) 8
adult (7) 7
breast cancer (7) 7
cancer (7) 7
chemotherapy (7) 7
medicine & public health (7) 7
aged (6) 6
cost-benefit analysis (6) 6
surgery (6) 6
aged, 80 and over (5) 5
biological and medical sciences (5) 5
medical sciences (5) 5
surgical oncology (5) 5
survival analysis (5) 5
breast neoplasms - mortality (4) 4
business & economics (4) 4
cost-effectiveness (4) 4
drug therapy (4) 4
economics (4) 4
filgrastim (4) 4
granulocyte colony-stimulating factor - economics (4) 4
granulocyte colony-stimulating factor - therapeutic use (4) 4
health care sciences & services (4) 4
health policy & services (4) 4
internal medicine (4) 4
social sciences (4) 4
united states (4) 4
abridged index medicus (3) 3
analysis (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic agents - therapeutic use (3) 3
breast neoplasms - drug therapy (3) 3
health care costs (3) 3
health economics (3) 3
health policy (3) 3
mammography (3) 3
medical prognosis (3) 3
multivariate analysis (3) 3
neoplasm recurrence, local (3) 3
neoplasm staging (3) 3
neutropenia (3) 3
neutropenia - chemically induced (3) 3
neutropenia - prevention & control (3) 3
original research (3) 3
pegfilgrastim (3) 3
polyethylene glycols (3) 3
prevention (3) 3
public health, environmental and occupational health (3) 3
quality-adjusted life years (3) 3
recombinant proteins (3) 3
recurrence (3) 3
risk factors (3) 3
survival (3) 3
women (3) 3
anesthesia. intensive care medicine. transfusions. cell therapy and gene therapy (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
blood. blood and plasma substitutes. blood products. blood cells. blood typing. plasmapheresis. apheresis (2) 2
breast neoplasms - therapy (2) 2
cancer patients (2) 2
care and treatment (2) 2
cost-utility (2) 2
decision support techniques (2) 2
fever - chemically induced (2) 2
fever - economics (2) 2
fever - prevention & control (2) 2
florida (2) 2
general & internal medicine (2) 2
granulocyte colony-stimulating factor (2) 2
growth factors (2) 2
hematology (2) 2
macrophage colony stimulating factor (2) 2
melanoma - secondary (2) 2
metastases (2) 2
neoplasm recurrence, local - prevention & control (2) 2
neutropenia - economics (2) 2
pharmacology & pharmacy (2) 2
pharmacology. drug treatments (2) 2
practice guidelines as topic (2) 2
primary prophylaxis (2) 2
prognosis (2) 2
proportional hazards models (2) 2
prospective studies (2) 2
research (2) 2
sensitivity and specificity (2) 2
transfusions. complications. transfusion reactions. cell and gene therapy (2) 2
tumors (2) 2
united states - epidemiology (2) 2
african americans (1) 1
african continental ancestry group (1) 1
algorithms (1) 1
ambulatory care - economics (1) 1
amputation (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Value in health, ISSN 1098-3015, 2009, Volume 12, Issue 2, pp. 217 - 225
Internal Medicine | cost-effectiveness | breast cancer | pegfilgrastim | primary prophylaxis | cost‐effectiveness | Primary prophylaxis | Pegfilgrastim | Breast cancer | Cost-effectiveness | Economics | Social Sciences | Life Sciences & Biomedicine | Health Care Sciences & Services | Business & Economics | Health Policy & Services | Science & Technology | Breast Neoplasms - economics | Granulocyte Colony-Stimulating Factor - economics | United States | Humans | Middle Aged | Risk | Recombinant Proteins | Fever - chemically induced | Filgrastim | Fever - economics | Antineoplastic Agents - adverse effects | Neutropenia - mortality | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Decision Making | Quality-Adjusted Life Years | Primary Prevention - economics | Polyethylene Glycols | Risk Assessment | Risk Reduction Behavior | Risk Factors | Decision Support Techniques | Probability | Neutropenia - economics | Granulocyte Colony-Stimulating Factor - therapeutic use | Breast Neoplasms - drug therapy | Health Care Costs | Secondary Prevention - economics | Cost-Benefit Analysis | Neutropenia - prevention & control | Breast Neoplasms - mortality | Fever - prevention & control | Aged | Women | Oncology, Experimental | Health insurance industry | Research | Peptide hormones | Prevention | Chemotherapy | Granulocyte colony-stimulating factor | Analysis | Macrophage colony stimulating factor | Universities and colleges | Growth factors | Cancer | Index Medicus
Journal Article
Journal Article
Journal of oncology practice, ISSN 1554-7477, 01/2011, Volume 7, Issue 1, pp. 17 - 18
Journal Article
Journal of oncology practice, ISSN 1554-7477, 07/2009, Volume 5, Issue 4, pp. 165 - 166
Journal Article
Journal of oncology practice, ISSN 1554-7477, 05/2008, Volume 4, Issue 3, pp. 114 - 115
Journal Article
Journal of oncology practice, ISSN 1554-7477, 2008, Volume 4, Issue 4, pp. 193 - 194
Journal Article
Journal of oncology practice, ISSN 1554-7477, 2008, Volume 4, Issue 5, pp. 236 - 237
Journal Article
Journal of oncology practice, ISSN 1554-7477, 07/2007, Volume 3, Issue 4, pp. 187 - 188
Journal Article
PharmacoEconomics, ISSN 1170-7690, 6/2012, Volume 30, Issue 6, pp. 497 - 511
Quality of Life Research | Health Economics | Health Administration | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | Healthcare-expenditure | Pegfilgrastim | Febrile-neutropenia | Granulocyte-colony-stimulating-factors | Cost-effectiveness | Cost-utility | Filgrastim | Neutropenia | Economics | Social Sciences | Life Sciences & Biomedicine | Health Care Sciences & Services | Pharmacology & Pharmacy | Business & Economics | Health Policy & Services | Science & Technology | Toxicity: blood | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Drug toxicity and drugs side effects treatment | Miscellaneous (drug allergy, mutagens, teratogens...) | Immunomodulators | Drug Costs | Economics, Pharmaceutical | Biosimilar Pharmaceuticals - therapeutic use | Granulocyte Colony-Stimulating Factor - economics | United States | Europe | Humans | Antineoplastic Agents - therapeutic use | Biosimilar Pharmaceuticals - economics | Neutropenia - economics | Granulocyte Colony-Stimulating Factor - therapeutic use | Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use | Fever - chemically induced | Neoplasms - drug therapy | Fever - economics | Antineoplastic Agents - adverse effects | Cost-Benefit Analysis | Neutropenia - prevention & control | Fever - prevention & control | Neutropenia - chemically induced | Granulocyte-Macrophage Colony-Stimulating Factor - economics | Cost-effectiveness; Cost-utility; Febrile-neutropenia; Filgrastim; Granulocyte-colony-stimulating-factors; Healthcare-expenditure; Neutropenia; Pegfilgrastim. | Prevention | Usage | Economic aspects | Research | Growth factors | Medical care, Cost of | Cancer
Journal Article